Integral Diagnostics Ltd · ASX:IDX
Integral Diagnostics — Shareholder Meeting (November 2021)
18 slides from Integral Diagnostics's shareholder meeting presentation, Nov 5, 2021
Slide 1: AGM Presentations by the Chair and Managing Director/CEO
T | +61 3 5339 0704 E | info@integraldiagnostics.com.au Suite 9.02, level 9, 45 William St Melbourne Vic 3000 www.integraldiagnostics.com.au AGM Presentations by the Chair and Managing Director/CEO 5 November 2021, Melbourne Attached are copies of the presentations to be given to shareholders by the
Slide 2: Chair Address
Chair Address Helen Kurincic
Slide 3: Financial Highlights
FINANCIAL HIGHLIGHTS FY21 36.1% 25.3% 23.5% 14.5% 27.3% 19.3% 6.7% increase in increase in increase in increase in increase in increase in improved statutory operating operating operating operating free cash net debt NPAT NPAT EBITDA EPS revenue flow /LTM EBITDA $31.3m $38.1m $93.5m 19.0cps $348.8m
Slide 4: Governance Highlights
GOVERNANCE HIGHLIGHTS Board Governance model for specialised medical business includes two Radiologist Executive Directors. Board Executive Director succession, Dr Chien Ho stepped down from the Board in March and Dr Nazar Bokani was appointed to take over from Dr Ho. New Zealand (NZ) Advisory Board
Slide 5: Managing Director and CEO Presentation
Managing Director and CEO Presentation Dr Ian Kadish
Slide 6: Strong, Consistent Performance
STRONG, CONSISTENT PERFORMANCE Operating Revenue ($m) Operating EBITDA ($m) 27.3% 348.8 274.1 23.5% 93.5 231.0 75.7 179.7 188.0 167.8 53.0 34.9 38.1 33.5 FY16 FY17 FY18 FY19 FY20 FY21 FY16 FY17 FY18 FY19 FY20* FY21* Operating NPAT ($m) Operating Diluted Earnings Per Share (cps) 25.3% 14.5% 38.1 19.0
Slide 7: Delivering on Our Values in FY21
DELIVERING ON OUR VALUES IN FY21 Patients Medical Everyone Create Embrace First Leadership Counts Value Change • Served 797,118 • 237 reporting • 1,524 employees • Increased Operating • Managed workflows, patients radiologists NPAT by 25.3% to personnel & systems • Reduced lost time • Serviced 35,26
Slide 8: Share Price Performance
SHARE PRICE PERFORMANCE ASX IDX $6.00 10,500 9,500 $5.00 8,500 $4.00 7,500 $3.00 6,500 5,500 $2.00 4,500 $1.00 3,500 2,500 $0.00 Oct-15 Apr-16 Oct-16 Apr-17 Oct-17 Apr-18 Oct-18 Apr-19 Oct-19 Apr-20 Oct-20 Apr-21 Oct-21 ASX IDX Integral Diagnostics AGM 2021 7
Slide 9: IDX Operates in Key Geographic Markets
IDX OPERATES IN KEY GEOGRAPHIC MARKETS Total IDX Geographic Queensland Western Victoria & Victoria New Zealand Queensland IDX Corporate Market & NSW Australia NSW Ballarat, Albury, Geelong, Sunshine Gold Coast, South West Wodonga, Melbourne & Warrnambool Coast, Core markets Toowoomba Western Aucklan
Slide 10: Diagnostic Imaging (DI) Industry Growth Australia
DIAGNOSTIC IMAGING (DI) INDUSTRY GROWTH AUSTRALIA Industry growth rates in Australia impacted by COVID-19 in CY20, return of strong industry growth rates in CY21 off a lower base Published industry data is not available for the New Zealand market Integral Diagnostics AGM 2021 9
Slide 11: Regulatory Environment
REGULATORY ENVIRONMENT Australia: MRI Licences • No further MRI licences have been announced. MRI licences and/or changes may occur in a Federal election year May 2021 Budget • Indexation of 90% of MBS items, or 80% of benefits at a rate of 0.9% from 1 July 2021, vs CPI of 3.8% and Health CPI of 4.8
Slide 12: Completion of the Acquisition of The X-Ray Group
COMPLETION OF THE ACQUISITION OF THE X-RAY GROUP A leading practice in Albury-Wodonga on the Victorian/New South Wales Border • Completed on 1/11/21 • Comprises 5 radiology clinics - 2 comprehensive clinics in Albury and Wodonga, and 3 community clinics in Wangaratta, Yarrawonga and Lavington • Empl
Slide 13: FY22 Key Priorities and Focus
FY22 KEY PRIORITIES AND FOCUS • Manage ongoing impact of COVID-19 • Manage the changing competitive landscape with regards to hospitals and referrers • Drive further organic growth and efficiency gains • Educate patients, payors and referrers on new MRI and PET technologies • Accelerate digital tech
Slide 14: FY22 Strategy and YTD Trading Update
FY22 STRATEGY AND YTD TRADING UPDATE 1 Grow existing business and margin 2 Strategic expansion Strategy Nurture and Execute on our Continue to evaluate further develop Key Priorities Increased focus Accelerate use environment, strategic expansion culture and on brownfields of digital and social and
Slide 15: Appointment of Chief Medical Officer
APPOINTMENT OF CHIEF MEDICAL OFFICER Appointed Dr Lisa Sorger as Chief Medical Officer (CMO) in June 2021. Graduate of the University of Western Australia Medical School Trained as a radiologist with special interests in women’s and body imaging Extensive experience as a radiologist, a director of m
Slide 16: FDG PET Scans for Diagnosis of Alzheimers Type Dementia
FDG PET SCANS FOR DIAGNOSIS OF ALZHEIMERS TYPE DEMENTIA FDG PET scan for the diagnosis of Alzheimer’s type dementia has been approved by the Australian Government Department of Health • Legislative framework finalised by 1 November 2021 and included in the Budget 21/22 announcements • Dementia is th
Slide 17: IDX Senior Leadership Team
IDX SENIOR LEADERSHIP TEAM CMO appointment augments the IDX Senior Leadership Team, consistent with the extensive growth of the business. The CFCO role will transition in January 2021. Recruitment is well advanced. Dr Ian Kadish Anne Lockwood Managing Director Chief Financial and and Chief Executive
Slide 18: Good Medicine is Still Good Business
Good Medicine is Still Good Business
Integral Diagnostics — Shareholder Meeting (November 2021) on 6ix